YBX1 in Breast Cancer: From Molecular Mechanisms to Therapeutic Opportunities

Authors

  • Houhong wang Department of General Surgery, The Affiliated Bozhou Hospital of Anhui Medical University, China Author
  • Shang Bian Department of General Surgery, The Affiliated Bozhou Hospital of Anhui Medical University, China Author

DOI:

https://doi.org/10.47363/JSAR/2025(6)226

Keywords:

female malignancies , cancer-related deaths globally , therapies, Triple-Negative Breast Cancer (TNBC), HER2+ subtypes, immunotherapy

Abstract

Breast cancer, a heterogeneous malignancy with high metastatic potential, remains a global health burden. The Y-box binding protein 1 (YBX1), a multifunctional nucleic acid-binding protein, has emerged as a pivotal regulator in breast cancer progression, mediating Epithelial-Mesenchymal Transition (EMT), Cancer Stem Cell (CSC) maintenance, and therapeutic resistance. This review synthesizes preclinical and clinical evidence from 2023–2025, detailing YBX1’s structural features, molecular mechanisms in tumorigenesis, prognostic/diagnostic significance, and emerging therapeutic strategies. Data from 12+ cohorts (n > 2,500) demonstrate that high YBX1 expression correlates with poor survival (HR = 2.15, P < 0.001) and treatment resistance. Targeting YBX1 via small molecules,
RNA therapies, and immune combinations shows promise in preclinical models, highlighting its potential as a precision oncology target.

Author Biographies

  • Houhong wang, Department of General Surgery, The Affiliated Bozhou Hospital of Anhui Medical University, China

    Department of General Surgery, The Affiliated Bozhou Hospital of Anhui Medical University, China

  • Shang Bian, Department of General Surgery, The Affiliated Bozhou Hospital of Anhui Medical University, China

    Department of General Surgery, The Affiliated Bozhou Hospital of Anhui Medical University, China

Downloads

Published

2025-06-18

Issue

Vol. 6 No. 6 (2025): Special Issue: Cell Biology

Section

Articles